Research

Urine carcinoembryonic antigen levels are more useful than serum levels for early detection of Bilharzial and non-Bilharzial urinary bladder carcinoma: Observations of 43 Egyptian cases

Gamal M Saied¹, Wafaa H El-Metenawy², Mohamed S Elwan¹ and Nazar R Dessouki*³

Address: ¹Department of General Surgery, Faculty of medicine, Cairo University, Cairo, Egypt, ²Department of Radiation Oncology, Faculty of Medicine, Cairo University, Cairo, Egypt and ³Department of General Surgery, St. Bernard’s Hospital, Gibraltar, UK

Email: Gamal M Saied - gamal462004@yahoo.com; Wafaa H El-Metenawy - metnawi@link.net; Mohamed S Elwan - karim_gsaied@hotmail.com; Nazar R Dessouki* - nazar_dessouki@doctors.org.uk

* Corresponding author

Abstract

Background: Both urinary bilharziasis and urothelial neoplasia are associated with increased production of tissue carcinoembryonic antigen (CEA).

Patients and methods: Urine and serum CEA were determined in 43 patients with urinary bladder carcinoma including 22 post bilharzial and 21 nonbilharzial cases, in addition to 10 normal control cases.

Results: A significant increase was detected in both urine and serum CEA levels with bladder carcinoma compared to control cases. Urinary CEA was significantly elevated in 86% of bilharzial, versus 62% in nonbilharzial bladder carcinoma. Only 10.5% of control cases had urinary CEA elevation. The mean urinary CEA in bilharzial, was higher than that of nonbilharzial carcinoma, but the difference was not statistically significant. There was a definite relationship between urine CEA and the stage of malignancy; the higher the stage, the higher the level of urine CEA. No relationship could be detected between the stage of malignancy and serum CEA, or between the grades of malignancy and urine or serum CEA levels.

Conclusion: Urinary CEA is more useful than serum CEA in the early detection of urotherial carcinoma particularly if provoked by bilharziasis. Its level is also correlated with the tumor stage.

Background

Carcinoembryonic antigen (CEA) a specific product of neoplasia derived from the endoderm and is supposed to have a potential value in screening, diagnosis and follow-up of patients suspected of having urothelial carcinoma [1]. It has also been detected in other types of normal human tissue including prostate, uterus and spleen. This aroused fears of false positive results and of compromising specificity if further enhancement of sensitivity was tried [2]. Urinary CEA measurement and cytological examination are two noninvasive procedures that were compared and found to yield similar frequencies of positivity. Simultaneous performance of these two tests increased the yield of positive results to 86% [3]. It was
also suggested that assay of urinary CEA might provide an alternative to urinary cytology for industrial screening of high-risk population. In hospital practice, it was thought to be useful alongside cytology and cystoscopy in primary diagnosis and routine follow-up of patients with urothelial tumors after treatment to detect early recurrences. It was also found to add to the information of T classification [4,5]. The finding that T1 and in situ carcinoma can yield raised values of CEA is of potential importance as it is this group of tumors which is difficult to detect by urinary exfoliative cytology [6].

Urinary CEA was first suggested to be particularly helpful to evaluate urothelial dysplasia [7] and in patients with bilharzial chronic cystitis it may afford a valuable screening test for premalignant lesions and malignant transformation [8,9].

Raised serum CEA was recorded in association with invasive tumors or the presence of metastatic disease [10,11]. With regards CEA tissue level, it was found to be higher in malignant vesical urothelium than in the control group, concentrations were much higher with infiltrating tumors [12]. Normalization of CEA level in follow-up of treated cases points to successful management [13]. On the other hand, local recurrence or multiple metastases were found to be associated with elevated CEA [14].

Bilharzial carcinoma of the urinary bladder was found to represent a distinct clinico-pathological entity different from nonbilharzial carcinoma [15]. The aim of this study is to throw light on the value of urinary and serum CEA in the diagnosis of carcinoma of the urinary bladder and to see if there is any difference between bilharzial and non-bilharzial carcinoma as regards production of CEA, a new point not handled before.

Patients and methods
This study was conducted at Kasr El-Aini University Hospitals, Cairo/Egypt from April 2002 through April 2005. Forty three patients having proven carcinoma of the urinary bladder beside 10 control cases were enrolled in the study and categorized into three groups. Group I included 22 patients having bilharzial carcinoma; group II included 21 patients having nonbilharzial carcinoma while group III consisted of 10 normal controls with no infection or malignancy of the urinary tract or malignancy elsewhere. Radical cystectomy was done to patients of the first two groups. Transurethral resection was not attempted even in early lesions due to the prevalence of multicentricity in bilharzial cases and to standardize the treatment procedure.

For every case, urine and serum CEA were measured. Patients showing evidence of acute urinary tract infection were excluded. Samples of 10 ml of midstream morning urine were collected. Samples with 5 pus cells or more/HPF were discarded. Five ml of blood were obtained from fasting individuals after at least 6 hours of stopping smoking. No additives or preservatives were necessary to maintain the integrity of the specimens. Grossly hemolysed samples were discarded. CEA was measured in both urine and serum by monoclonal enzyme immunoassay (EIA) method using a commercially available kit from Abbott. The normal adult range by this method is less than 3 ng/ml in serum and less than 30 ng/ml in urine. Insignificant minimal elevations are found in heavy smokers.

For patients with carcinoma of the urinary bladder, the following was done: a detailed clinical history was taken and patients with a positive history of bilharziasis were excluded from group II, but this was not sufficient to put them in group I. Secondary bacterial infections were excluded before enrollment as it may affect urinary CEA values. No evidence that bilharziasis alone (in the absence of frank premalignant lesions or cellular dysplasia) has such effect [8]. Clinico-pathological examination included bimanual examination to assess operability particularly in bilharzial carcinoma where the mobility (not the size) is important. Staging was done according to the TNM system of UICC [16] for non-bilharzial cases it was done by CT scans and confirmed postoperatively on the resected specimens. Cystoscopic examination and biopsy were performed. Radical cystectomy was done for all cases and the specimens were examined for type and grade of malignancy, pathological staging and the presence or absence of associated bilharzial cystitis.

Results
There was a definite relationship between the stage of malignancy and the level of urine CEA, the higher the stage the higher the level of urine CEA. There was no relationship between the stage of malignancy and the level of serum CEA or between the grade of malignancy and the levels of both urine and serum CEA. The evidence was observed using correlation coefficient (r). Table 1 shows the relation of urine and serum CEA levels with type, grade and stage in bilharzial carcinoma. The relation is direct with correlation coefficient 0.131 at p = 0.0236. Table 2 shows same relation in non-bilharzial cases (correlation coefficient is -0.25 at p = 0.0007). In control cases correlation coefficient was 0.60 at p = 0.065. Finally Table 3 compares the percentage of cases with high levels of urine and serum CEA in the three groups. Table 4 show percentage of cases having urine CEA above 10 ng/ml and serum CEA above 5 ng/ml.

Discussion
Since CEA is present in the normal urothelium, destruction and regeneration of urothelial cells due to tumor or
inflammation might release CEA into the urine [17]. It was suggested by some authors that elevated urinary CEA values, once infection is excluded, are specific to urothelial carcinoma, as the levels are normal in association with nonurothelial tumors such as hypernephroma, prostatic and colorectal carcinoma [16]. Even if the plasma levels are raised, the urinary levels rise only when such tumors involve the urinary tract by infiltration. Urinary CEA like activity was found to be increased in 61% of patients with transitional cell carcinoma of the bladder [3]. On the other hand, serial measurement of serum CEA was noted to judge response of advanced urothelial tumors to chemotherapy [18]. In this series, after exclusion of acute infection, urine CEA levels were raised in 86% of patients with bilharzial carcinoma and in 62% of patients with nonbilharzial carcinoma of the urinary bladder. There was also a significant difference between urine CEA in cancer patients and in the controls.

Morning samples of urine were shown to be more informative because of the benefit of overnight exposure of urine to the tumor [11]. On the other hand, 24 hour urinary CEA was advised to be measured, as it was shown to be more informative being elevated in 81% of patients with active tumors [7]. In this series, CEA was measured in the morning samples of urine only.

Urinary infection was found to spoil the use of urinary CEA as a diagnostic procedure [11]. The simple presence of bacteria in the urine irrespective of their identity or number has no influence on urinary CEA [19]. It is the inflammation of the urothelium that is responsible for the production and release of CEA. Therefore, only in the presence of symptoms and signs, and in the presence of pyuria, urinary tract infection is considered to exist. Infection was considered to be present if 5 leukocytes/HPF or more exist in the urine [17]. On the other hand, the effect of infection can largely be eliminated by routine use of midstream specimens of urine and its examination for pus cells.

Table 1: CEA in urine and serum, histopathological type, grade of malignancy and pathological stage of bilharzial carcinoma of the urinary bladder.

| Case no | Urine CEA | Serum CEA | Histological type | Grade of malignancy | Pathological staging |
|---------|-----------|-----------|-------------------|---------------------|---------------------|
| 1       | 55        | 5         | Squamous cell     | II                  | P2                  |
| 2       | 47        | -         | Squamous cell     | I                   | P2                  |
| 3       | 9         | 7         | Squamous cell     | I                   | P1                  |
| 4       | 72        | -         | Squamous cell     | I                   | P2                  |
| 5       | 40        | 7         | Squamous cell     | II                  | P2                  |
| 6       | 140       | 4         | Squamous cell     | I                   | P3                  |
| 7       | 114       | 7         | Squamous cell     | III                 | P3                  |
| 8       | 33        | 17        | Squamous cell     | II                  | P2                  |
| 9       | 10        | -         | Squamous cell     | I                   | P2                  |
| 10      | 13        | -         | Squamous cell     | I                   | P2                  |
| 11      | 4         | 35        | Squamous cell     | I                   | P1                  |
| 12      | 14        | 8         | Squamous cell     | II                  | P2                  |
| 13      | 85        | 0         | Transitional cell | III                 | P2                  |
| 14      | 105       | 0         | Squamous cell     | II                  | P3                  |
| 15      | 100       | 5         | Transitional cell | II                  | P2                  |
| 16      | 70        | 1         | Squamous cell     | I                   | P3                  |
| 17      | 28        | 0         | Squamous cell     | II                  | P2                  |
| 18      | 270       | 9         | Adenocarcinoma    | III                 | P3                  |
| 19      | 135       | 35        | Squamous cell     | I                   | P3                  |
| 20      | 20        | 0         | Squamous cell     | III                 | P2                  |
| 21      | 105       | 8         | Squamous cell     | II                  | P2                  |
| 22      | 165       | 0         | Transitional cell | II                  | P3                  |

Mean urine CEA in bilharzial carcinoma: 75.09 ng/ml (Standard deviation: 64.26 ng/ml)
Mean serum CEA in bilharzial carcinoma = 5.03 ng/ml (Standard deviation = 5.41 ng/ml)
cases only serum CEA levels were raised with normal urinary CEA levels.

With nonmetastatic bladder carcinoma, plasma CEA levels in one study were raised only in 42% of the patients, but with the development of extravesical metastatic spread, the incidence of raised plasma CEA values increased to 85% [6]. On the other hand, in a case report, CEA was elevated with the development of adenocarcinoma in the reconstructed bladder following ileocystoplasty [21]. Some authors also stressed the use of plasma CEA in assessing response to chemotherapy in advanced bladder cancer [22]. In this series, serum CEA levels were raised in 39% of patients with bilharzial carcinoma of the urinary bladder and in only 10.5% of control cases. This indicates that serum CEA is of little diagnostic value in carcinoma of the urinary bladder although there was a significant difference between the mean of serum CEA in patients with carcinoma and the controls. There were no documented cases with distant metastases but the patients

Table 2: CEA in urine and serum, histopathological type, grade of malignancy and pathological stage of nonbilharzial carcinoma of the urinary bladder.

| Case No | Urine CEA (ng/ml) | Serum CEA (ng/ml) | Histological Type | Grade | Stage |
|---------|------------------|------------------|-------------------|-------|-------|
| 1       | 22               | 8                | Transitional      | III   | P3    |
| 2       | 10               | 10               | Transitional      | III   | P1    |
| 3       | 14               | --               | Transitional      | III   | P2    |
| 4       | 30               | --               | Transitional      | III   | P3    |
| 5       | 8                | 4                | Anaplastic        | IV    | P2    |
| 6       | 26               | 3.5              | Transitional      | III   | P2    |
| 7       | 160              | 2.5              | Transitional      | III   | P3    |
| 8       | 17               | 3                | Transitional      | III   | P1    |
| 9       | 13               | 3                | Transitional      | III   | P2    |
| 10      | 3                | 5                | Transitional      | III   | P1    |
| 11      | 165              | 0.5              | Transitional      | III   | P2    |
| 12      | 135              | 0.5              | Anaplastic        | IV    | P3    |
| 13      | 15               | 0.5              | Transitional      | II    | P2    |
| 14      | 4                | 0.5              | Transitional      | II    | P2    |
| 15      | 120              | 1                | Transitional      | III   | P3    |
| 16      | 75               | 3                | Transitional      | II    | P1    |
| 17      | 3                | 1                | Transitional      | II    | P1    |
| 18      | 5                | 0                | Squamous          | III   | P3    |
| 19      | 5                | 3                | Transitional      | III   | P2    |
| 20      | 1                | 0                | Transitional      | III   | P2    |
| 21      | 90               | 3                | Squamous          | II    | P1    |

Mean for urine CEA in non-bilharzial carcinoma = 43.86 ng/ml. (Standard deviation = 55.70 ng/ml)
Mean for serum CEA in non-bilharzial carcinoma = 2.74 ng/ml. (Standard deviation = 2.68 ng/ml)
Mean urine CEA in squamous cell carcinoma = 58.26 ng/ml. (Standard deviation = 42.12 ng/ml)
Mean urine CEA in transitional cell carcinoma = 50.14 ng/ml. (Standard deviation = 58.31 ng/ml)
Mean serum CEA in squamous cell carcinoma = 5.60 ng/ml. (Standard deviation = 5.41 ng/ml)
Mean serum CEA in transitional cell carcinoma = 2.37 ng/ml. (Standard deviation = 2.79 ng/ml)

Table 3: CEA in urine and serum of the control cases.

| Case No. | Urine CEA (ng/ml) | Serum CEA (ng/ml) |
|----------|------------------|------------------|
| 1        | 1                | 2                |
| 2        | 0                | 2                |
| 3        | 1                | 1.5              |
| 4        | 0                | 2                |
| 5        | 0.5              | 2.5              |
| 6        | 1.5              | 1.5              |
| 7        | 0                | 1                |
| 8        | 2                | 0.5              |
| 9        | 2                | 0.5              |
| 10       | 1                | 0.5              |

Mean for urine CEA in of control cases = 0.9 ng/ml (Standard deviation = 0.77 ng/ml)
Mean for serum CEA of control cases = 1.4 ng/ml (Standard deviation = 0.74 ng/ml)
with raised serum CEA levels in this series might have spread to the regional lymph nodes or have distant micrometastases elsewhere in the body.

Regarding the tumor stage, some authors have found a correlation between it and the level of CEA in urine, the higher the stage the higher the level [3,5,23,24] However, others found no correlation [7,10,11,19,25] In this series, a definite relationship was found between the stage of malignancy and the levels of urinary CEA in the urine; the higher the stage the higher the level of CEA. On the other hand, serum CEA was in another study found to increases with increasing extent of cancer [3]. On the contrary, no correlation was found in the present study [5,10,11]. In this series, no relationship could be detected between the stage of malignancy and the level of serum CEA.

Many authors found no correlation between the grade of malignancy and urine CEA levels [1,5-7,19,25,26]. However, others have advocated that the less differentiated the tumor, the higher is the level of CEA in the urine [3]. In this series, no correlation was found between the urinary CEA levels and the different grades of malignancy.

The levels of urinary CEA in this series in bilharzial carcinoma were higher than the levels in nonbilharzial carcinoma, though the difference was insignificant (P > 0.05 and < 0.10). This difference may be attributed to the associated chronic cystitis which is always present in bilharzial carcinoma as chronically stimulated urothelium forms CEA at an increased rate, and therefore increased release of CEA in the urine occurs [5,27]. It was also found by some authors that in premalignant bilharzial lesions, CEA in the urine reached levels as high as those encountered in frank bladder malignancy [8]. These premalignant lesions in association with bilharzial carcinoma may lead to this increase in CEA production. The other proposed cause for this difference is the tumor mass, as bilharzial carcinoma tends to be more bulky [15], and according to some authors, CEA in the urine increases with the increase in the size of the tumor [6,19,23,26]. This difference is not due to the histopathological difference between bilharzial and nonbilharzial carcinoma as no difference could be detected between urinary CEA in squamous cells carcinoma and transitional cell carcinoma in this series.

Conclusion
Estimation of urine CEA can be useful in the early detection of carcinoma of the urinary bladder among high-risk people, particularly if provoked by bilharziasis. It adds more data to the staging of tumors, and hence to the prognosis after treatment.

Competing Interests
The authors declare that they have no competing interest.

Authors’ contributions
GMS: Chief author. created the idea, co-author selection, participated in the design of the study, performed clinical work and drafted the manuscript

WHEI-M: Carried out immunoassay, revised the manuscript draft

MSE: Participated in the clinical work, participated in the design of the study and performed the statistical analysis (cooperating with a specialist statistician)

NRD:Approved study design, participated in the sequence alignment, drafted the manuscript, revised references and revised final copy before delivery [Correspondent]

All authors read and approved the final manuscript

References
1. Hall RR, Laurence DJR, Darcy D, Stevens U, James R, Roberts S. Neville AM: Carcinoembryonic antigen in the urine of patients with urothelial carcinoma. Br Med J 1972, 3:609-611.
2. Nagao K, Hisatomi H, Hirata H, Yamamoto S, Hikiji K, Yamamoto M, Kanamaru T: Expression of molecular marker genes in various types of normal tissue: implication for detection of micrometastases. Int J Mol Med 2002, 10:307-310.
3. Fraser RA, Ravry MJ, Segura JW, Go VL: Clinical evaluation of urinary and serum carcinoembryonic antigen in bladder cancer. J Urol 1975, 114:226-229.
4. Hall RR, Laurence DJ, Neville AM, Wallace DM. Carcinoembryonic Antigen and urothelial carcinoma. Br J Urol 1973, 45:88-92.
5. Zimmerman R, Wahren B, Edsmyr F. Assessment of serial CEA determinations in urine of patients with bladder carcinoma. Cancer 1980, 46:1802-1809.
6. Neville AM, Nery R, Hall RR, Turberville C, Laurence DJ: Aspects of the structure and clinical role of the carcinoembryonic antigen (CEA) and related macromolecules with particular reference to urothelial carcinoma. Br J Cancer Suppl 1973, 1(Suppl 1):198-207.
7. Murphy WM, Vandevoorde JP, Rao MK, Soloway M. The clinical value of urinary Carcinoembryonic antigen-like substances in urothelial cancer. J Urol 1977, 118:806-808.
8. El-Menawy WH, El-Razky YS, Mahfouz S, Shukry I, Abdin M, Hashem T, Hashem B, El-Haddad S. Value of urinary carcinoembryonic antigen and urinary CEA in diagnosis after treatment.
bryonic antigen (CEA) in the early detection of malignant transformation of bilharzial bladder. J Egypt Nat Cancer Inst 1987, 3:195.
9. Alsabti EA, Kamel A: Carcinoembryonic antigen (CEA) in patients with malignant and non-malignant diseases. Neoplasma 1979, 26:603-609.
10. Turner AG, Carter S, Higgins E, Glashan RW, Neville RW, Neville AM: The clinical diagnostic value of the carcinoembryonic antigen (CEA) in haematuria. Br J Urol 1977, 49:61-66.
11. Coombers GB, Hall RR, Laurence JR, Neville AM: Urinary carcinoembryonic antigen (CEA) like molecules and urothelial malignancy: A clinical appraisal. Br J Cancer 1975, 31:135-142.
12. Moreno Sierra J, Chicharro Almaraz GJ, Torronteras Santiago JM, Ortega Heredia MD, Maaestro De las Casas ML, Silmi Moyano A, Resel Estevez L: [Advances regarding tumor markers in bladder cancer]. [Article in Spanish]. Actas Urol Esp 1997, 21:195-205.
13. Soma I, Hasuike Y, Hayashi N, Fukuchi N, Izawa H, Yoshida T, Ebisui G, Sawaki I, Fujimoto T, Koshino T, Izumiya A: [A case report – Efficacy of combination therapy to unresectable advanced gall bladder carcinoma-palliative operation, hepatic arterial infusion therapy, and radiation therapy]. [Article in Japanese]. Hinyokika Kyo 2004, 50:99-102.
14. Gamal G, Khalil A: Rectosigmoid cystoplasty after cystectomy for bilharzial bladder carcinoma: A preliminary report. Egypt J Surg 1987, 6(2):29.
15. El-Bolkainy MN, Tawfik HN, Kamel LA: Histopathologic classification of carcinomas in the schistosomal bladder in detection of bladder cancer associated with schistosomiasis. Edited by: El-Bolkainy NN, Chu KW. Cairo, Egypt; Al-Ahram Press: 1981:106.
16. Tsugawa M: Immunological and biochemical characterization of urinary carcinoembryonic antigen and its clinical significance. Nippon Hinyokika Gakkai Zasshi 1992, 83:1600-1608.
17. Maezawa T, Yonese J, Tsukamoto T: [Combinationchemotherapy with cisplatin and ifosfamide in patients with advanced renal cell carcinoma]. [Article in Japanese]. Nippon Hinyokika Gakkai Zasshi 2001, 92:727-735.
18. Tailly G, Cornelissen M, Vereecken RL, Verduyn H, Devos P, De Roo M: Urinary carcinoembryogenic antigen (CEA) in the diagnosis and follow-up of bladder carcinoma. Br J Urol 1983, 55:501-507.
19. Stefanovic V, Mitic-Zlatkovic M, Ignjatovic I, Vlajkovic M, Scepovic Z: Tissue polypeptide antigen and carcinoembryonic antigen lack diagnostic accuracy in urothelial carcinoma. Int Urol Nephrol 1999, 31:443-449.
20. Ishida T, Koizumi H: [A case of adenocarcinoma of the reconstructed bladder following ileocystoplasty]. [Article in Japanese]. Nippon Hinyokika Gakkai Zasshi 1997, 88:439-442.
21. Cook IS, Huddart RA, Jay G, Norman A, Dearnley DP, Horwich A: The utility of tumour markers in assessing the response to chemotherapy in advanced bladder cancer. Br J Cancer 2000, 82:1952-1957.
22. Guinan P, John T, Sadoughi N, Ablin RJ, Bush I: Urinary carcinoembryonic antigen like antigen level in patients with bladder carcinoma. J Urology 1974, 111:350-352.
23. Ionescu C, Romas NA, Ionescu L, Bennett S, Tannenbaum M, Yeeman RN, Latsmmer JK: Carcinoembryonic antigen and bladder carcinoma. J Urology 1976, 115:46-48.
24. Colleen S, Eb A, Guiberg B, Johannson BG, Lindberg LG, Olsson AM: CEA in urine in patients with urothelial Carcinoma. Scand J Urology and Nephrology 1979, 13:149-153.
25. Wahren B: Cellular content of carcinoembryonic antigen in urothelial carcinoma. Cancer 1978, 42(3):1533-1539.
26. Jaurtze G, Altenahr E: Immunohistochemical demonstration of carcinoembryonic antigen CEA and its correlation with grading and staging on tissue sections of urinary bladder carcinomas. Cancer 1982, 50(10):2052-2056.